

Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation

## CASE REPORT FORM

Protocol number BIG 1-06 / EGF 106903

Amended survival follow-up from Protocol Amendment 5 Approval

Centre No.			
Subject No.			

## Amended survival FU from Protocol Amendment 5 Approval

Informed consent Protocol number BIG 1-06 / EGF106903 Centre No. Subject No. Page 216 Did the patient sign the Main Informed Consent version nb \_\_\_\_\_ corresponding to Protocol Amendment 5? □ No ☐ Yes → Specify date of consent below Date Main Informed Consent was signed? Did the patient sign the Main Informed Consent version nb corresponding to Protocol Amendment nb ? □ No ☐ Yes → Specify date of consent below Date Main Informed Consent was signed? Did the patient sign the PGx Informed Consent version nb \_\_\_\_\_ corresponding to Protocol Amendment nb\_\_\_\_\_? □ No ☐ Yes → Specify date of consent below Date PGx Informed Consent was signed? All data entered in this case report form have been entered under my authority and to the best of my knowledge are accurate and complete. Investigator's signature (A medically qualified sub-investigator is allowed to sign the CRF if he/she is listed on the form FDA 1572) Date